The testing will start at CDC’s regional labs in the first quarter of HP’s fiscal 2019 (between November and January). Its initial focus is on widely resistant bacteria. And HP won’t be done once the bioprinters are in the Center’s hands. HP will help the CDC study the success of the pilot, tweak it if needed, and explore the possibility of wider-scale printer uses if the test proves successful. This may become an instrumental part of fighting superbugs if all goes smoothly.